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2ABSTRACT
There is a currently a need to develop adjuvants that are best suited to simultaneously enhance 
immune responses, induce immunologic memory, improve patient compliance (i.e., reduce doses 
and inflammation), and provide vaccine shelf stability for stockpiling and global deployment to 
challenging environments. Biodegradable polyanhydrides have been investigated extensively to 
overcome such challenges. It has been shown that controlling copolymer composition can result 
in chemistry-dependent immunomodulatory capabilities. These studies have revealed that 
copolymers rich in sebacic acid (SA) are highly internalized by antigen presenting cells and 
confer improved shelf stability of encapsulated proteins, while copolymers rich in 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) also exhibit enhanced internalization by and 
activation of antigen presenting cells (APCs), in addition to providing superior retention of 
protein stability following encapsulation and release. However, to date CPTEG:SA copolymers 
have not been synthesized and described. In this work, we hypothesized that new copolymers 
composed of CPTEG and SA would combine the advantages of both monomers in terms of 
enhanced thermal properties, maintaining antigenicity of encapsulated proteins following 
nanoparticle synthesis, and superior cellular internalization and activation by APCs, 
demonstrated by the upregulation of costimulatory markers CD80, CD86, and CD40, as well as 
the secretion of proinflammatory cytokines IL-6, IL-1β, and TNF-α. Herein, we describe the 
synthesis and design of novel CPTEG:SA nanoparticles with improved thermal properties, 
payload stability, and internalization by antigen presenting cells for applications in vaccine 
delivery. The performance of these new CPTEG:SA formulations was compared to that of 
traditional polyanhydride copolymers.
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3INTRODUCTION
There are many challenges associated with developing vaccination strategies to prevent 
pathogens from establishing infection in the host. With the advent of recombinant subunit 
protein-based vaccines, the need has increased to develop adjuvants that are best suited to 
enhance immune responses, induce immunologic memory, improve patient compliance (i.e., 
reduce doses and inflammation), and provide vaccine shelf stability for stockpiling and 
deployment to harsh environments. While traditional adjuvants enhance immune responses, 
some of them (e.g., MPLA, aluminum-based salts) induce inflammation and adverse reactions at 
the injection site1 and must be refrigerated for extended storage, limiting their use for long term 
storage or in harsh environments2. 
Nanoparticle-based technologies have long been investigated as a delivery vehicle/adjuvant 
system for vaccines3. It has been shown that nanoparticle characteristics, such as size4, shape5,6, 
charge7, and chemistry8 can be used to control cellular uptake, and ligation of the polymer can 
aid in targeting draining lymph nodes9, thus enabling targeted delivery of the payload. These 
beneficial properties have enabled the design of nanoparticle-based systems that are being widely 
investigated as vaccine adjuvant platforms against infectious disease8,10–18 and for targeted 
delivery of tumor antigens and immune therapies against cancer19–21.
Biodegradable polymer-based nanoparticle systems are promising for vaccine delivery due to 
their facile synthesis, ability to protect encapsulated proteins from enzymatic degradation, and 
erosion-controlled sustained release22 or pulsatile release mechanisms23. Poly(lactic-co-glycolic 
acid) (PLGA) is the most widely investigated polymer in this category and is FDA-approved for 
human use, showing promise for vaccine delivery24. However, PLGA exhibits bulk erosion 
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4which, along with the relatively high acidity of its degradation products (pKa glycolic acid: 
3.8325; lactic acid: 3.0826), can cause denaturation of encapsulated proteins27.
Biodegradable polyanhydrides have also been investigated extensively to overcome such 
challenges and meet the abovementioned vaccine requirements28. Comprised of 1,6-bis(p-
carboxyphenoxy) hexane (CPH), 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), and 
sebacic acid (SA), these materials are safe, biodegradable, exhibit mild inflammation, and are 
currently FDA-approved to treat malignant glioblastomas29–31. Controlling copolymer 
composition has been shown to enhance cellular uptake32,33, ultimately resulting in chemistry-
dependent immunomodulatory capabilities34,35. These materials represent an efficacious vaccine 
adjuvant platform, as evidenced by sustained antibody responses to numerous antigens10,11,15,16,36, 
enhanced germinal center formation37, increased cytotoxic T cell responses38, and protection 
against multiple bacterial and viral infections10,13,17. 
Previous work has shown that SA-rich chemistries are highly internalized by antigen presenting 
cells32 (APCs) and confer improved shelf stability of encapsulated proteins39. CPTEG-rich 
chemistries also exhibit enhanced internalization by and activation of APCs32, in addition to 
providing superior retention of protein stability following encapsulation and release39. In this 
work, we hypothesized that new copolymers composed of CPTEG and SA would combine the 
advantages of both monomers in terms of enhanced thermal properties, maintaining antigenicity 
of encapsulated proteins following nanoparticle synthesis, and superior activation of APCs. Here, 
we describe the synthesis and design of novel CPTEG:SA nanoparticles with improved thermal 
properties, payload stability, and APC activation for applications in vaccine delivery. The 
performance of these novel nanoparticles was compared to that of the more commonly used 
20:80 CPTEG:CPH and 20:80 CPH:SA nanoparticles.
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5MATERIALS AND METHODS
Materials
Sebacic acid (99%), bovine serum albumin, and chemicals used for CPTEG and CPH diacid and 
polymer synthesis, including 1,6-dibromohexane, triethylene 4-p-hydroxybenzoic acid, and 1-
methyl-2-pyrrolidinone were purchased from Sigma-Aldrich (St. Louis, MO). Chloroform, 
petroleum ether, ethyl ether, hexanes, sodium hydroxide, toluene, sulfuric acid, acetonitrile, 
dimethyl formamide, acetic anhydride, methylene chloride, pentane, and potassium carbonate 
were purchased from Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile was purchased 
from Apollo Scientific (Cheshire, UK). Deuterated chloroform used for 1H NMR analysis was 
purchased from Cambridge Isotope Laboratories (Andover, MA). RAW 264.7 and J774 cells 
were purchased from American Type Culture Collection (ATCC; Manassas, VA) and were used 
for assays. 
Animals
Female BALB/c mice (6−7-week-old) were purchased from Charles River Laboratories 
(Wilmington, MA). The Institutional Animal Care and Use Committee (IACUC) at Iowa State 
University approved all protocols involving animals.
Copolymer Synthesis and Characterization
CPTEG and CPH diacids were synthesized as previously described35,40. CPTEG:CPH and 
CPH:SA copolymer synthesis was performed using melt polycondensation40. For synthesis of the 
novel CPTEG:SA copolymer, 2 g of total monomer (the mass of each monomer varied 
depending on copolymer composition) and 90 mL of acetic anhydride were added to a 100 mL 
round bottom flask and reacted for 30 min at 125 °C in an oil bath. The acetic anhydride was 
removed using a rotary evaporator, and the dried product was then reacted for 1 h at 140 °C in an 
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6oil bath under vacuum (0.2 torr). The solid product was dissolved in approximately 20 mL of 
methylene chloride overnight and precipitated in 1 L hexanes to isolate the copolymer. At least 
three batches of each copolymer chemistry were synthesized in this work. Copolymer 
composition and molecular weight of each batch of copolymer synthesized were estimated using 
end group analysis of 1H NMR (DXR 500, Bruker) spectra. Copolymer thermal properties (glass 
transition temperature and melting point) were measured using differential scanning calorimetry 
(Q2000, TA Instruments, New Castle, DE), using a heating rate of 10 °C/min. The relative 
crystallinity of CPTEG:SA copolymers was determined using wide angle X-ray diffraction 
(Siemens D500, Siemens/Bruker). 
The number average sequence length, degree of randomness, and reactivity ratios of CPTEG:SA 
copolymers was determined from 1H NMR spectra, using methods described previously41. Films 
were prepared for contact angle measurements by dissolving copolymer in methylene chloride at 
50 mg/mL, 300 µL was pipetted on a 6 cm glass slide, heated to 80 °C for 10 s and spin coated 
(WS-650Mz-23NPPB, Laurell Technologies, North Wales, UK) for 30 s at 2000 rpm with a 
1500 rpm/s acceleration rate. An average of eight contact angle measurements of each chemistry 
of CPTEG:SA films was performed using a goniometer (NRL 100, ramé-hart, Succasunna, NJ) 
with 2 µL droplets of nanopure water. 
Erosion Kinetics
Films were prepared by dissolving copolymers in methylene chloride at a concentration of 150 
mg/mL and allowed to dry overnight. The scintillation vials containing dried copolymer were 
then heated to their respective melting points for one minute and then allowed to cool to room 
temperature. 15 mL of nanopure water was pipetted into each vial and 15 mL was removed and 
replaced daily over 45 days of study. Samples were lyophilized, the dry mass was weighed, and 
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7the cumulative mass was determined over the course of the study. In separate vials, samples of 
the film were collected on days 15, 30, and 45, the film samples lyophilized, dissolved in 
deuterated DMSO, and characterized for copolymer composition by 1H NMR. 
Nanoparticle Synthesis and Characterization
For protein stability characterization, CPTEG:SA nanoparticles, either empty or encapsulating 
the model antigen ovalbumin (OVA, at 5% w/w), were synthesized via flash nanoprecipitation, 
as previously described15. For release kinetics experiments, CPTEG:SA nanoparticles 
encapsulating the model protein bovine serum albumin (BSA, at 2% w/w) were spray dried using 
a Büchi B90 HP spray dryer (Büchi, Flawil, Switzerland). Briefly, for spray dried nanoparticle 
synthesis, polymer was dissolved in chloroform at 10 mg/mL with 5 mM sodium dioctyl 
sulfosuccinate as an emulsifier. BSA was dissolved in nanopure water at 4 mg/mL, pipetted at a 
1:20 (water:solvent) ratio into the solvent, and emulsified with the polymer via sonication for 30 
s. The emulsion was spray dried at room temperature (pump rate 10%, spray rate 100%, gas flow 
rate 100 L/min, inlet temperature ~30 ºC). CPTEG:SA nanoparticles were imaged using 
scanning election microscopy (SEM; JEOL 840 A, JEOL Ltd., Tokyo, Japan), and nanoparticle 
mean size and size distribution were determined using ImageJ (National Institutes of Health, 
Bethesda, MD). Nanoparticle zeta potential was measured using Zetasizer Nano (Malvern 
Instruments, Worcester, UK). 
Protein Characterization
For characterization of OVA released from 5% (w/w) CPTEG:SA nanoparticles, 5 mg of each 
nanoparticle formulation was suspended in 250 µL of nanopure water, sonicated for 
approximately 15 seconds, and the samples were allowed to release overnight (~18 h), after 
which the samples were centrifuged at 15,000 rcf for 5 min and 200 µL supernatant was 
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8removed. The protein released was quantified via micro bicinchoninic acid assay, and the 
samples were diluted to 40 µg/mL for Native PAGE gel analysis (see below). To determine 
changes in the tertiary structure of the protein, the samples (40 µg/mL) were excited at a 
wavelength of 280 nm and the emission was measured over the range of 300 – 450 nm using a 
SpectraMax M3 fluorescent spectrometer (Molecular Devices, Sunnyvale, CA). To determine 
changes in the secondary structure of the protein, circular dichroism spectra were acquired using 
a Jasco J-715 spectrophotometer (Jasco Analytical Instruments, Easton, MD) of the samples (20 
µg/mL) over a range of 195 – 260 nm.
Native PAGE Gel Analysis
Native PAGE gel analysis was performed using release supernatants from flash nanoprecipitated 
5% OVA-loaded CPTEG:SA nanoparticles. Sample concentrations were adjusted to 20 µg/mL, 
then diluted with an equal volume of native sample buffer (Bio-Rad, catalog # 161-0738), and 25 
µL of each diluted sample was added to the respective wells of a polyacrylamide gel (4-20% MP 
TGX Gel 10W 30 µL, Bio-Rad, catalog #4561093). The gel was subjected to 150 V for 60 min 
using 25 mM Tris, 192 mM glycine running buffer, placed in fixative solution (40% (v/v) 
ethanol, 10% (v/v) acetic acid) for three hours, and then stained overnight using flamingo 
fluorescent gel stain (Bio-Rad, catalog # 161-0491). The stained gel was imaged using a 
Typhoon 9400 flatbed scanner (GE Healthcare, Pittsburgh, PA).
ELISA
ELISA analysis of OVA released from CPTEG:SA nanoparticles was performed as previously 
described10. Briefly, high-binding Costar 590 EIA/RIA microtiter plates (Corning) were coated 
overnight with 100 µL of a 0.5 µg/mL solution of OVA released from the nanoparticles at 4 °C. 
The microtiter plates were then dumped and blocked for two hours with 2.5% (w/v) powdered 
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9skim milk dissolved in PBS-Tween with 0.05% Tween 20, pH 7.4, that had been incubated for 
two hours at 56 °C to inactivate any endogenous phosphatase activity. Following block, 
microtiter plates were washed thrice with PBS-T. Pooled serum obtained from OVA-immunized 
mice was added at a dilution of 1:200 and serially diluted in PBS-T containing 1% (v/v) goat 
serum. Each sample was tested in duplicate. Following incubation overnight at 4°C, plates were 
washed thrice with PBS-T, after which the secondary antibody alkaline phosphatase-conjugated 
goat anti-mouse IgG heavy and light chain (Jackson ImmunoResearch) was added at a dilution of 
1 µg/mL. Plates were incubated for two hours at room temperature and then washed thrice with 
PBS-T. 100 µL of alkaline phosphatase substrate (Fisher Scientific, Pittsburgh, PA) was added to 
each well at a concentration of 1 mg/mL dissolved in 50 mM sodium carbonate, 2 mM 
magnesium chloride buffer at pH 9.3 for colorimetric development. Plates were analyzed after 30 
min using a SpectraMax M3 microplate reader at a wavelength of 405 nm. Titer is reported as 
the reciprocal of serum dilution at which the optical density (OD) value was at most 0.2, a 
conservative endpoint greater than the average OD of saline-mouse serum, at a 1:200 dilution, 
plus two standard deviations.
Protein Release Kinetics
For protein release characterization, approximately 5 mg of 2% (w/w) BSA-loaded CPTEG:SA 
nanoparticles was suspended in 250 µL of PBS, sonicated for 30 s, and placed on a shaker 
incubator at 37 ºC. 200 µL were removed and replaced with fresh PBS at indicated time points, 
and released protein was measured via micro bicinchoninic acid assay (Thermo Fisher Scientific, 
Waltham, MA). Following 30 days of release, the buffer was changed to 40 mM sodium 
hydroxide to catalyze the release of any remaining protein and this information was utilized to 
determine the encapsulation efficiency, which was calculated as the total amount of protein 
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10
released divided by the theoretical amount of protein used for nanoparticle synthesis. The 
encapsulation efficiency of BSA in the various CPTEG:SA nanoparticle formulations ranged 
between 33-40%. 
Differentiation of Bone Marrow-derived Dendritic Cells (BMDCs)
Bone marrow was harvested from femurs and tibia of BALB/c mice and differentiated into 
dendritic cells using a protocol previously described42. Briefly, bone marrow isolates were 
harvested by flushing the tibia or femur with 10% FBS RPMI. Cells were counted and 
subsequently plated on petri dishes at 4 x 106 cells/plate in 10 mL media. 10 ng/mL of 
granulocyte macrophage colony stimulating factor (GM-CSF) was added to the plates on day 0 
and fresh GM-CSF and media was added on day 3. On days 6 and 8 of culture, 10 mL of media 
was replaced with fresh GM-CSF and media, and the cells harvested on day 10 for nanoparticle 
stimulation assays.
Biocompatibility and Cellular Internalization of CPTEG:SA Nanoparticles
For biocompatibility assays, the murine RAW 264.7 monocyte/macrophage cell line was seeded 
in flat bottom 96 well tissue culture plates at a density of 100,000 cells/well (100 µL) and 
allowed to adhere overnight. The following morning, 100 µL was added to the wells containing 
empty CPTEG:SA nanoparticles at concentrations ranging from 500 µg/mL serially diluted two-
fold down to 7.8 µg/mL for 24 hours, after which 25 µL of MTT reagent (2.5 mg/mL) was added 
to the wells and allowed to react for two hours. The entire volume was carefully pipetted off and 
300 µL DMSO was added to the wells and absorbance measurements were made at 540 nm, 
using 690 nm as a background subtraction. The cell viability was calculated as the background 
corrected absorbance of the samples divided by the background corrected absorbance of 
unstimulated cells. 
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11
For cell internalization, the murine J774 monocyte/macrophage cell line, human THP-1 cell line, 
and murine BMDCs were seeded in flat bottom 24 well tissue culture plates at cell density of 
500,000 cells/well (500 µL cell culture media) and allowed to adhere overnight. The following 
morning, 500 µL culture media was added to the wells containing CPTEG:SA nanoparticles 
encapsulating CdxSe1-x/ZnScore/shell fluorescent nanocrystals (1% w/w; excitation 405 nm; 
emission 450 nm; Cytodiagnostics, Burlington, Ontario, Canada) at a concentration of 125 
µg/mL for 2.5 h, after which the cells were scraped, fixed, and the samples assessed for 
nanoparticle-positive cells via flow cytometry. In order to properly differentiate nanoparticles 
and nanocrystals from cells, control tubes were also analyzed containing solely the nanocrystal-
loaded nanoparticles in addition to a tube containing nanocrystals alone suspended in buffer.
APC Activation by CPTEG:SA Nanoparticles
For cell activation studies, RAW 264.7 cells were seeded in flat bottom 24 well tissue culture 
plates at a cell density of 500,000 cells/well (500 µL cell culture media) and allowed to adhere 
overnight. The following morning, 500 µL cell culture media was added to the wells containing 
CPTEG:SA nanoparticles at a final concentration of 62.5 µg/mL for 24 h, after which 500 µL of 
cell culture supernatant was collected to evaluate the levels of cytokine secretions using a 
BioRad BioPlex 200 system (Hercules, CA). The cytokines IL-6, IL-1β, IL-17, TNF-α, IL-12, 
IL-10, IFN-γ, IL-5, IL-2, and IL-4 were assayed for. 
The cells were scraped and transferred to polystyrene FACS tubes. Prior to labeling the cells, the 
Fc receptors were blocked with 1 mg/mL rat IgG (Sigma-Aldrich, St. Louis, MO) and 10 µg/mL 
anti-CD16/32 (eBioscience). Following 10 min of block, the cells were stained with 
fluorescently conjugated antibodies for CD80 (Biolegend, PerCP-Cy5.5, clone 16-10A1), CD86 
(eBioscience, FITC, clone GL1), and CD40 (eBioscience, APC, clone 1C10) diluted at a 1:100 
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v/v in FACs buffer. Following 30 min of staining, the cells were washed in FACS buffer to 
remove excess dye and fixed using BD stabilizing fixative (BD Bioscience, Franklin Lakes, NJ). 
Flow cytometry analysis was performed using FlowJo (FlowJo, LLC, Ashland, OR) following 
data collection on a FACSCanto II (BD Bioscience, Franklin Lakes, NJ).
RESULTS
CPTEG:SA copolymers were synthesized with the following criteria in mind: 1) thermal 
properties of the copolymers must be above body temperature (37 ºC) to maintain discreteness of 
the nanoparticles and encapsulated protein stability at in vivo temperatures, 2) synthesized 
nanoparticles must be discrete to maintain suspension quality for ease of administration, and 3) 
nanoparticles must maintain antigenicity of protein during encapsulation and release. Once these 
criteria were met, the nanoparticles were evaluated for their biocompatibility and APC 
internalization and cellular activation.
CPTEG:SA copolymer structural characterization
CPTEG:SA copolymers were synthesized by varying CPTEG molar composition from 0 – 25 
mol%. Batches of the CPTEG:SA copolymers in molecular weight ranges of 10,000-20,000 Da 
resulted in an oily substance (data not shown) that was unsuitable for further processing; 
however, increasing the reaction time to maintain the molecular weight of each batch of 
CPTEG:SA copolymer between 20,000-30,000 Da resulted in a solid mass for all copolymers 
synthesized (Table 1). It should be noted that CPTEG:SA copolymers with >25 mol% CPTEG 
were not studied further because the copolymers were less solid, sticky, and failed to result in 
discrete nanoparticles (data not shown).
Table 1. CPTEG:SA copolymer characterization   
Chemistry Molecular Weight (Daltons)
Melting Point 
(°C)
Relative Crystallinity 
(%)
Degree of 
Randomness
poly(SA) 10466 - 18727 76.7 ± 2.0 58.7 1
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5:95 CPTEG:SA 20119 - 24062 74.6 ± 1.8 55.7 2.6
10:90 CPTEG:SA 20601 - 29083 70.0 ± 1.9 48 2.2
15:85 CPTEG:SA 20571 - 24944 64.5 ± 2.4 40.6 2.1
20:80 CPTEG:SA 19978 - 30828 58.9 ± 3.2 35 2.1
25:75 CPTEG:SA 25578 - 31455 52.3 ± 3.5 26 2.1
1H NMR spectra of these copolymers revealed characteristic peaks associated with CPTEG40 and 
SA41, with aromatic CPTEG proton peaks located in the δ = 6.8-8.1 ppm range, and inner chain 
proton peaks located between 3.6-4.4 ppm (Figure 1A). Characteristic SA proton peaks were 
located between 1.35-2.65 ppm. As expected, increasing the molar ratio of CPTEG in the 
copolymer backbone resulted in an increase in the proton peaks associated with CPTEG and the 
copolymer composition matched that of the feed composition, consistent with previous studies 
with CPH:SA and CPTEG:CPH copolymers40,41,43. Further analysis of 1H NMR spectra of 
CPTEG:SA copolymers revealed a decrease in average sequence length with increasing CPTEG 
content, in line with previous reports for other polyanhydride copolymers (Figure 1B)41,44. All 
copolymers studied exhibited alternating or random copolymer formation, evidenced by degree 
of randomness values of approximately 2.0 (Table 1). This was further confirmed by calculating 
the reactivity ratios r1 and r2, which were determined to be r1 = 1.0 – 1.8 and r2 = 1.0 – 1.8 using 
the Mayo-Lewis method, or r1 = 1.46 and r2 = 1.01 using the Fineman-Ross method, indicating 
that either monomer can be added to the copolymer backbone at comparable rates, as is the case 
for random copolymers.
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Figure 1. Characterization of CPTEG:SA copolymers using 1H NMR spectroscopy. 
(A) Molecular structure of CPTEG:SA copolymer. (B) 1H NMR spectra of CPTEG:SA 
copolymers. (C) Description of hydrogens in copolymer backbone for 1H NMR spectra. 
(D) Number average sequence lengths of repeating CPTEG or SA units determined 
from 1H NMR spectra.
Thermal analysis of the copolymers demonstrated increased melting temperatures with 
increasing SA molar composition, ranging from 52 °C for 25:75 CPTEG:SA to 78 °C for 
poly(SA) (Figure 2A and Table 1). A glass transition temperature was not detected in any of the 
copolymer chemistries in the temperature ranges studied. Wide angle X ray diffraction analysis 
of powders revealed semi-crystalline properties of all copolymers analyzed, with an increase in 
relative crystallinity with increasing SA molar composition, ranging from 26% for 25:75 
CPTEG:SA to 59% for poly(SA) (Figure 2B and Table 1). The relative crystallinity of 10:90 
CPTEG:SA closely matched that of the 20:80 CPH:SA copolymer control, whose relative 
crystallinity has previously been reported to be ca. 47%45. 20:80 CPTEG:CPH is an amorphous 
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polymer and therefore does not contain any crystals40. Therefore, CPTEG:SA copolymers 
demonstrate characteristic properties consistent with those previously observed in other 
polyanhydride copolymers and the investigated copolymer chemistries exhibited desirable 
thermal properties that may be useful for vaccine stability in vivo and long-term shelf storage. 
Figure 2. Thermal properties and crystallinity of CPTEG:SA copolymers using 
DSC and WAXD. (A) Heat flow vs. temperature plot of CPTEG:SA copolymer powders 
measured with differential scanning calorimetry (DSC). The melting point was 
determined by the minima of the endotherm of each chemistry. (B) Wide angle X ray 
diffraction (WAXD) spectrogram of CPTEG:SA copolymer powders.
Erosion Kinetics of Polyanhydride Films
To assess the relative erosion kinetics of CPTEG:SA copolymers compared to traditional 
polyanhydride copolymers, copolymer films were prepared for contact angle measurements to 
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determine their hydrophobicity, followed by characterization of their erosion kinetics. 
Interestingly, contact angle measurements of CPTEG:SA films of various copolymer 
compositions revealed that hydrophobicities were relatively similar across copolymer 
composition, with 10:90 CPTEG:SA having the highest contact angle (76°) and 80:20 
CPTEG:SA having the lowest (57°) (Figure 3A). The erosion kinetics data demonstrated a more 
rapid erosion profile for all CPTEG:SA copolymers studied compared to that of 20:80 
CPTEG:CPH and 20:80 CPH:SA films (Figure 3B). The erosion rate of CPTEG:SA films 
increased with increasing SA molar composition (approximately 150-200 mg eroded over 45 
days), compared to 20:80 CPTEG:CPH and 20:80 CPH:SA films, which had approximately 100 
and 50 mg eroded over 45 days, respectively. This trend was also observed with the release of 
BSA from spray dried 2% (w/w) CPTEG:SA nanoparticles, in which increasing SA content 
resulted in a more rapid release of encapsulated protein (Figure 3C). 1H NMR analysis of 
copolymer film samples performed at 15, 30, and 45 days revealed a decrease in SA composition 
in the films over time, indicating that SA-SA bonds are more water labile than CPTEG-CPTEG 
or CPTEG-SA bonds (Table 2). Therefore, CPTEG:SA copolymers exhibit rapid erosion rates 
compared to conventional 20:80 CPTEG:CPH and 20:80 CPH:SA copolymers and the rate of 
erosion can be tuned by modulating copolymer composition.
Page 16 of 40
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17
Figure 3. CPTEG:SA copolymers demonstrate chemistry-dependent erosion 
kinetics. (A) Contact angle measurements of CPTEG:SA copolymer films prepared via 
spin coating on glass slides. (B) Mass of CPTEG:SA copolymer films eroded as a 
function of time. 15 mL supernatants were collected daily and the entire volume was 
replaced with fresh nanopure water. (C) Cumulative mass % released from spray dried 
2% (w/w) BSA-loaded CPTEG:SA nanoparticles. Statistical significance for contact 
angle measurements was determined via an ordinary one-way ANOVA with a Tukey’s 
multiple comparison test. Differences in letters above each copolymer chemistry 
indicate significant differences (p ≤ 0.05) in contact angle measurements between the 
various copolymers.
Table 2. CPTEG:SA copolymer film composition over time
Chemistry Time point Mole Fraction CPTEG
Mole Fraction 
SA
5:95 CPTEG:SA Day 15 0.05 0.95
Day 30 0.06 0.94
Day 45 0.06 0.94
15:85 CPTEG:SA Day 15 0.28 0.72
Day 30 0.28 0.72
Day 45 0.38 0.62
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25:75 CPTEG:SA Day 15 0.39 0.61
Day 30 0.38 0.62
Day 45 0.48 0.52
CPTEG:SA Nanoparticles Stabilize Protein Payloads and Provide Sustained Release
Nanoparticles based on CPTEG:SA copolymers were synthesized in order to assess the size, 
discreteness, and ability to encapsulate and release antigenically stable protein (hen egg 
ovalbumin was used as a model antigen in these studies). Empty particles synthesized using flash 
nanoprecipitation method were discrete, with sizes ranging from 575 – 1054 nm, and with 
narrow size distributions (Figure 4 and Table 3). These diameters are slightly larger than those 
typically reported for CPTEG:CPH (~200 nm) and CPH:SA (~400 nm) nanoparticles11,46. Zeta 
potential measurements of the nanoparticles showed zeta potentials ranging from -28.7 to -35.3 
mV, consistent with previous reports for other polyanhydride nanoparticles (Table 3)11. 
CPTEG:SA nanoparticles were investigated for their ability to encapsulate and release stable 
antigen. Native PAGE gel analysis of hen egg ovalbumin (OVA) released from 5% (w/w) OVA-
loaded CPTEG:SA nanoparticles demonstrated that all CPTEG:SA chemistries maintained the 
native conformational stability of the encapsulated antigen upon release (Figure 5A). Further 
analysis of OVA using circular dichroism revealed that the secondary structure of the released 
antigen was preserved (Figure 5B). In addition, fluorescence spectroscopy analysis of OVA 
revealed that the tertiary structure of released antigen was maintained (Figure 5C). Interestingly, 
there was a trend in increasing fluorescence signal from samples with higher CPTEG molar 
composition, matching that of the OVA standard. These studies indicated that CPTEG:SA 
nanoparticles can be synthesized into discrete nanoparticles that maintain protein stability 
following encapsulation and release.
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Figure 4. CPTEG:SA nanoparticle characterization. SEM images of empty 
CPTEG:SA nanoparticles synthesized via flash nanoprecipitation. Briefly, copolymer 
was dissolved in methylene chloride at a concentration of 20 mg/mL. The solution was 
poured into a bath of pentane at a 1:250 volumetric ratio (methylene chloride: pentane), 
and the resulting suspension was vacuum filtered to collect the nanoparticles. The 
mean diameter of the nanoparticles were as follows: poly(SA): 655.6 ± 197.3 nm; 5:95 
CPTEG:SA: 605.7 ± 284.2 nm; 10:90 CPTEG:SA: 575.3 ± 252.0 nm; 15:85 CPTEG:SA: 
619.6 ± 279.5 nm; 20:80 CPTEG:SA: 1054.3 ± 477.2 nm; 25:75 CPTEG:SA: 798.5 ± 
292.7 nm.
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Figure 5. CPTEG:SA nanoparticles maintain protein conformational stability 
following encapsulation and release. (A) Native PAGE gel analysis of OVA released 
from 5% (w/w) OVA-loaded CPTEG:SA nanoparticles. Released OVA concentration 
was measured via microBCA and diluted to 40 µg/mL for analysis. (B) Circular 
dichroism spectra of OVA released from 5% (w/w) OVA-loaded CPTEG:SA 
nanoparticles. Released OVA concentration was measured via microBCA and diluted to 
20 µg/mL for analysis. (C) Fluorescence spectra of OVA released from 5% (w/w) OVA-
loaded CPTEG:SA nanoparticles. Released OVA concentration was measured via 
microBCA and diluted to 40 µg/mL for analysis. Samples were excited at 280 nm and 
fluorescence was measured from 300-450 nm. 
Table 3. Characterization of CPTEG:SA nanoparticles
Chemistry Diameter(nm)
Polydispersity 
Index
Zeta Potential 
(mV)
poly(SA) 655.6 ± 197.3 0.09 -31.7 ± 6.7
5:95 CPTEG:SA 605.7 ± 284.2 0.22 -33 ± 9.3
10:90 CPTEG:SA 575.3 ± 252.0 0.19 -33.7 ± 8.9
15:85 CPTEG:SA 619.6 ± 279.5 0.20 -35.3 ± 9.0
20:80 CPTEG:SA 1054.3 ± 477.2 0.20 -29.6 ± 12.7
25:75 CPTEG:SA 798.5 ± 292.7 0.13 -28.7 ± 8.8
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CPTEG:SA Nanoparticles Are Biocompatible and Enhance Internalization and Activation 
of APCs
CPTEG:SA nanoparticles were evaluated for their biocompatibility as well as degree of 
internalization by APCs. An MTT assay performed on CPTEG:SA nanoparticles incubated with 
RAW 264.7 cells demonstrated that cells were >75% viable when incubated with nanoparticle 
concentrations of up to 62.5 µg/mL (Figure 6A). Interestingly, there was a trend in increasing 
cell viability with increasing CPTEG molar composition for concentrations >62.5 µg/mL. In 
comparison, both 20:80 CPTEG:CPH and 20:80 CPH:SA nanoparticles demonstrated similar 
biocompatibility, however these particles maintained higher cell viability at concentrations >62.5 
µg/mL. 
When CPTEG:SA nanoparticles were incubated with three different APC types, murine J774 
monocyte/macrophage cell line, human THP-1 monocyte/macrophage cell line, and murine 
BMDCs, the data showed a high degree of internalization of these particles by all three cell 
types. Formulations rich in SA displayed the highest degree of uptake across all three cell types, 
with a trend of increasing rates of internalization with increasing SA molar composition (Figure 
6B). Interestingly, depending on the cell type, 5:95 CPTEG:SA, 10:90 CPTEG:SA, and 15:85 
CPTEG:SA copolymers had rates of internalization greater than or equal to that of poly(SA) and 
the 20:80 CPH:SA controls, while 20:80 CPTEG:SA nanoparticles were internalized to the same 
degree of as poly(SA) in J774 and THP-1 cells, but not in BMDCs. The 25:75 CPTEG:SA 
nanoparticles had the lowest degree of internalization, significantly lower than that of all other 
CPTEG:SA formulations, with rates of internalization similar to that of the 20:80 CPTEG:CPH 
control. These results demonstrate the biocompatibility of CPTEG:SA nanoparticles and show 
that copolymer chemistries with molar composition ≤ 20 mol% CPTEG are highly internalized 
Page 21 of 40
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22
by APCs, with certain chemistries having enhanced internalization rates compared to poly(SA) 
and traditional polyanhydride nanoparticles.
Figure 6. CPTEG:SA nanoparticles are biocompatible and are internalized by 
antigen presenting cells. (A) MTT assay of CPTEG:SA nanoparticles incubated with 
the murine RAW 264.7 monocyte/macrophage cell line. Cells were incubated with 
varying concentrations of the empty nanoparticles for 24 h, after which MTT reagent 
was added to the wells to determine cell viability. The results shown are the average of 
two independent experiments for all chemistries except 20:80 CPH:SA, which is 
demonstrative of one independent experiment. (B) Cell internalization assay of 
CPTEG:SA nanoparticles incubated with the murine J774 monocyte/macrophage cell 
line, human THP-1 monocyte/macrophage cell line, and murine bone-marrow-derived 
dendritic cells. CPTEG:SA nanoparticles encapsulating fluorescent nanocrystals (1% 
w/w) were incubated with cells for 2.5 h at 125 µg/mL and flow cytometry analysis was 
performed to determine the percentage of nanoparticle-positive cells. Statistical 
significance was determined via an ordinary one-way ANOVA with a Tukey’s multiple 
comparison test. Differences in letters above each copolymer chemistry indicate 
significant differences (p ≤ 0.05) between the various treatment groups.
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As the CPTEG:SA nanoparticles were capable of being highly internalized by three various 
antigen presenting cell types, we next investigated their ability to activate RAW 264.7 cells in 
vitro. Following a 24 h stimulation of cells with CPTEG:SA nanoparticles, it was observed that 
all copolymer chemistries induced activation of RAW 264.7 cells, as evidenced by upregulation 
of the costimulatory cell surface markers CD40, CD80, and CD86 (Figure 7A). The levels of 
expression of these markers followed a similar trend to that observed with the internalization 
data (Figure 6B), where CPTEG:SA copolymers with 5-20% molar composition of CPTEG had 
greater than or equal levels of expression of these surface markers compared to poly(SA), 20:80 
CPTEG:CPH, and 20:80 CPH:SA nanoparticles. In addition, following 24 h stimulation, the 
proinflammatory cytokines TNF-α, IL-6, and IL-1β were detected in the cell culture 
supernatants, further indicating that these nanoparticle formulations are able to activate APCs. A 
similar trend to both internalization and costimulatory molecule expression was observed, with 
decreasing cytokine secretion levels detected from cells stimulated with nanoparticles of 
increasing CPTEG molar composition (Figure 7B). Overall, CPTEG:SA nanoparticles with 5-
20% CPTEG molar composition were able to induce secretion levels of all three cytokines 
greater than or equal to that of poly(SA) and the traditional polyanhydride nanoparticle controls. 
Interestingly, 5:95 CPTEG:SA nanoparticles were best able to induce IL-6 and IL-1β expression 
compared to poly(SA), as well as 20:80 CPTEG:CPH and 20:80 CPH:SA nanoparticles, which 
correlates with the internalization data presented in Figure 6B. We did not detect levels of 
secreted cytokines IFN-γ, IL-17, IL-12, IL-5, IL-2, IL-10, or IL-4. Overall, these data indicate 
the ability of CPTEG:SA nanoparticles to be internalized by and activate APCs, resulting in the 
expression of proinflammatory cytokines that can enhance immune responses.  
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Figure 7. CPTEG:SA nanoparticles activate antigen presenting cells and induce 
proinflammatory cytokine expression. RAW 264.7 cells were seeded at density of 500,000 
cells/well in a 24 well cell culture plate and stimulated with CPTEG:SA nanoparticles at a 
concentration of 62.5 µg/mL for 24 h. Lipopolysaccharide (LPS) was used as a positive control 
at a concentration of 1 µg/mL. (A) Mean fluorescence intensity (MFI) of cell surface markers 
following nanoparticle stimulation for 24 h, determined via flow cytometry. (B) Concentration of 
cytokines detected in cell culture supernatants following 24 h stimulation. Data are presented as 
a mean with standard deviation. Statistical significance was determined via an ordinary one-way 
ANOVA with a Tukey’s multiple comparison test. Differences in letters above each copolymer 
chemistry indicate significant differences (p ≤ 0.05) between the various treatment groups.
DISCUSSION
There is a growing body of literature on the efficacy of nanoparticles for protein therapeutics as 
well as novel adjuvants that enhance immune responses to vaccines, in particular subunit 
vaccines47–50. Polymeric nanoparticles are a promising class of carriers/adjuvants due to their 
facile synthesis and their ability to stabilize encapsulated payloads, ligate the polymer with 
various targeting ligands for targeted delivery, and tune release kinetics through 
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copolymerization. Polyanhydrides have been investigated as a protein and vaccine delivery 
platform due to their surface erosion characteristics, which enhances stability of encapsulated 
payloads39,51–53. In addition, their degradation products are less acidic than that of PLGA, with 
pKas of 5.8 & 8.4 (CPTEG)40, 3.7 & 6.7 (CPH)54, and 4.8 & 5.6 (SA)54. In this work, a new class 
of polyanhydride copolymers comprising of CPTEG and SA were synthesized in order to confer 
enhanced thermal properties for long term storage, ease of administration (discrete particles that 
suspend well), retention of protein stability following encapsulation and release, and improved 
uptake by and activation of APCs.
In addition to chemical properties of polymers being critical for maintaining protein 
conformational stability, maintaining thermal stability of both the antigen and the nanoparticle 
formulation is critical in the design of vaccines for long term storage39,55. Maintaining protein 
conformational stability is critical for developing robust immune responses to vaccines because 
linked recognition plays a role in the affinity maturation process of B cells in germinal centers56. 
Having the protein sequestered within a rigid polymer matrix with high thermal properties will 
allow for maintenance of protein stability during encapsulation and antigenicity of the payload 
upon release. In addition, high thermal properties can also help retain particle discreteness and 
morphology for long term storage, which would enable stockpiling vaccines for mass 
vaccination against highly lethal biodefense pathogens, or for deployment to harsh environments. 
We have previously shown that CPH:SA copolymers rich in SA were best able to maintain the 
activity of Bacillus anthracis protective antigen (PA) for at least four months, despite the 
inability of the copolymer to release antigenic protein compared to CPTEG:CPH copolymers39. 
This was attributed in part to the high glass transition temperature and melting points of this 
copolymer, though the exact mechanism has not been investigated. Hence, it was hypothesized 
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that copolymers of CPTEG and SA would have high thermal properties due to the high melting 
point (78 ºC) of poly(SA), and copolymerization with CPTEG would improve antigenicity of the 
released protein. In our studies, CPTEG molar compositions upwards of 25% yielded melting 
points of at least 52 ºC. These melting points are similar to those observed with CPH:SA 
copolymers (melting points of 20:80 CPH:SA and 50:50 CPH:SA are 66 ºC and 50 ºC, 
respectively45). 
Copolymers based on CPTEG:CPH or CPH:SA have demonstrated sustained release of 
encapsulated protein payloads over extended time periods, on the order of months57. In this 
work, it was observed that CPTEG:SA copolymers had faster erosion kinetics (on the order of 
weeks) than 20:80 CPTEG:CPH and 20:80 CPH:SA copolymers. The ability to tune the erosion 
rate was dictated by the copolymer composition, consistent with previous reports for 
CPTEG:CPH copolymers40. Despite having similar contact angles, chemistries rich in SA had 
the fastest rates of erosion and this was corroborated by 1H NMR spectroscopy measurements of 
the films over time, which showed that SA molar composition of the films decreased over time. 
This phenomena of rapid erosion of the CPTEG:SA copolymers compared to the traditional 
20:80 CPTEG:CPH and 20:80 CPH:SA copolymers is likely due to absence of CPH in the 
copolymer backbone, whose hydrophobicity is greater than that of SA and CPTEG22,40. Despite 
the fact that CPTEG is amorphous, which usually results in faster erosion kinetics in 
CPTEG:CPH copolymers54, and the similar contact angles measured between the various 
CPTEG:SA copolymers, increasing CPTEG molar composition resulted in a slower rate of 
erosion. This is likely due to the presence of aromatic rings present in CPTEG, which tends to 
slow the degradation rates of these copolymers58. These rapid erosion characteristics may be 
desirable for both drug and vaccine delivery, in order to have greater control over protein release 
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kinetics, or by cocktailing these nanoparticle chemistries with slower releasing copolymer 
formulations such as 20:80 CPTEG:CPH.
The hydrophobicity of polyanhydrides results in surface erosion characteristics, which in 
addition to higher pKa values, allows for protection of the structural stability of encapsulated 
proteins39,53,59. Copolymers containing CPTEG have previously demonstrated to maintain the 
stability of encapsulated proteins, with 50:50 CPTEG:CPH copolymers typically ideal for 
maintaining protein structure and antigenicity following release, presumably due to the lower 
acidity of degradative dicarboxylic acid products39,51–53. Despite the enhanced thermal properties 
of SA-rich chemistries (poly(SA) and 20:80 CPH:SA), it was previously shown that copolymers 
rich in SA resulted in loss of stability of B. anthracis protective antigen, and subsequently its 
antigenicity, which was attributed to the greater acidity of SA degradation products compared to 
CPTEG and CPH diacids39. Therefore, it was hypothesized that copolymerizing the more 
protein-favorable CPTEG with SA might result in an amphiphilic copolymer that can maintain 
protein structure and antigenicity following encapsulation and release. Our data showed that 
CPTEG:SA nanoparticles encapsulating OVA maintained protein stability via native PAGE gel 
analysis and circular dichroism, however it was observed that copolymers rich in CPTEG 
successfully maintained the tertiary structure of the OVA, which is likely attributable to the 
lower acidity of CPTEG. Therefore, the favorable high thermal properties of CPTEG:SA 
copolymers and inclusion of the less acidic CPTEG into the copolymer backbone make these 
copolymers an attractive candidate for protein encapsulation, as well as long term shelf storage.
Polyanhydride nanovaccines display chemistry-dependent cellular internalization and 
intracellular persistence by APCs which can aid in adjuvanting poorly immunogenic proteins. 
This has been observed to be enhanced in polymer chemistries rich in CPTEG molar 
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composition32, which had the highest degree of internalization and persistence in RAW 264.7 
macrophages8. In BMDCs, copolymer chemistries rich in SA had the highest percentage of 
cellular internalization, even greater than CPTEG-rich chemistries32. In this work, CPTEG:SA 
nanoparticles exhibited high rates of internalization by APCs. Interestingly, although previously 
poly(SA) nanoparticles had been shown to be the most highly internalized formulation32, 
multiple CPTEG:SA compositions (5:95 CPTEG:SA, 10:90 CPTEG:SA, and 15:85 CPTEG:SA) 
showed rates of internalization greater than or equal to that of poly(SA), depending on the cell 
type. The rates of internalization of the various nanoparticle chemistries appeared to correlate 
with the levels of costimulatory marker expression as well as proinflammatory cytokine secretion 
(Figure 7). By simultaneously examining cellular internalization, costimulatory cell surface 
marker expression, and cytokine secretion, it appears that there may be an optimal CPTEG:SA 
copolymer composition in the 5-15% CPTEG molar composition range that was best able to be 
internalized by and activate APCs. This observation is hypothesized to occur because of the 
synergy between the cellular internalization and activation mechanism(s) of CPTEG- and SA-
rich copolymers32,60, though the underlying mechanism by which this is occurring is not fully 
understood. Previous work has demonstrated actin-dependent internalization of various 
CPTEG:CPH and CPH:SA polyanhydride nanoparticle formulations61. Interestingly, varying 
copolymer composition had pronounced effects on whether cellular internalization was 
dependent on phagocytosis, micropinocytosis, clathrin- or caveolin-mediated endocytosis, or a 
combination thereof. This suggests that the mechanism of uptake of the CPTEG:SA copolymers 
may be finely dependent upon the copolymer composition, the cell type being targeted, and may 
likely be a combination of multiple cellular uptake mechanisms, with the 5-15% CPTEG molar 
composition range in the copolymer backbone being optimally internalized by such routes. 
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Further investigation into the mechanism by which APCs internalize these nanoparticles could 
dramatically improve targeted delivery of payloads to drive robust immune responses. 
CONCLUSIONS
In summary, this work described the synthesis and characterization of novel copolymers based 
on CPTEG and SA with favorable thermal properties for in vivo protein/vaccine delivery and 
long-term shelf storage. The CPTEG:SA nanoparticles maintain protein stability and antigenicity 
upon release, are biocompatible, and are highly internalized by APCs, resulting in increased 
expression of costimulatory cell surface marker expression and proinflammatory cytokine 
secretion, making them an attractive candidate for further study as a vaccine adjuvant/delivery 
system.
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